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ABSTRACT
Background. The rate of breast-conserving surgery (BCS)
is used as an esthetic outcome parameter, while other
treatments contribute also, such as neoadjuvant
chemotherapy (NAC) enabling BCS or immediate breast
reconstruction (IBR). This study explores these efforts to
preserve the patient’s breast contour.
Patients and Methods. All patients who underwent sur-
gery for invasive breast cancer in The Netherlands between
January 2011 and December 2015 were selected from the
Dutch national breast cancer audit (n = 61,309). The
breast-contour-preserving procedures (BCPP) rate was
defined as the rate of primary BCS, BCS after NAC, or
mastectomy with IBR. BCPP rates were calculated and
compared by year of diagnosis, age categories, and indi-
vidual hospitals.
Results. The rate of primary BCS remained stable (53%)
while the BCPP rate increased from 63% in 2011 to 71% in
2015 due to an increase in patients receiving BCS after
NAC and mastectomy with IBR. Primary BCS rates
increased with age (from 17% in patients aged\ 30 years
to 63% in patients aged 60–69 years), while the proportion
of patients undergoing mastectomy with IBR decreased
from 44% in patients \ 30 years to 1% in patients
C 70 years. The BCPP rate was similar for all age groups
except for patients[ 70 years. BCPP rates varied between
the different hospitals in The Netherlands, ranging from 47
to 88%.
Conclusions. The chance of preserving the breast contour
for patients with breast cancer has increased substantially
over recent years. BCPP provides a comprehensive
parameter of esthetic outcome of breast cancer surgery.
The quality of breast cancer treatment has received
considerable attention in recent years. Identification of
parameters that represent quality of breast cancer care is
challenging. As survival rates for patients with primary
breast cancer have improved considerably over the recent
decades1 and local recurrence rates have decreased sig-
nificantly,2 more effort is being directed to improve
esthetic outcomes, reflecting an important aspect of quality
of life. Previously, the proportion of patients undergoing
breast-conserving surgery (BCS) has been used as a
parameter reflecting esthetic outcome in breast cancer
treatment. Recent population-based studies report
stable BCS rates over the past years of approximately
60%,3,4 suggesting that esthetic outcomes of local treat-
ment may not have improved over recent years.
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Nonsurgical treatment modalities contribute to local
esthetic outcome as well. The use of neoadjuvant systemic
therapy influences the ability to perform BCS.5,6 Moreover,
immediate breast reconstruction following mastectomy
(IBR) or delayed breast reconstruction may also lead to
desirable esthetic outcomes. Both neoadjuvant
chemotherapy (NAC) and IBR are increasingly being
used,4 and institutional preferences regarding the use of the
former and surgical expertise with the latter have an impact
on the surgical choice for BCS or mastectomy.
A parameter that comprises the combined efforts to
preserve the breast contour may therefore be more appro-
priate to evaluate local esthetic outcome in breast cancer
treatment. For this purpose, we defined ‘‘breast-contour-
preserving procedure (BCPP)’’ as a parameter that
encompasses all strategies to preserve the contour of the
breast (primary BCS, BCS after NAC, and mastectomy
with IBR). Within the NABON Breast Cancer Audit
(NBCA),3 we explored BCPP as a local outcome parameter
by evaluating trends over time in relation to age, and
compared the frequencies of BCPP with primary BCS
rates.
PATIENTS AND METHODS
Data Source
Demographic and clinicopathological patient character-
istics (age, histological subtype, grade, tumor–node–
metastasis (TNM) classification) together with compre-
hensive multidisciplinary treatment information (surgical
and medical adjuvant and neoadjuvant therapy) were col-
lected prospectively for all newly diagnosed Dutch patients
with breast cancer in the NABON Breast Cancer Audit
(NBCA) since 2011.4 Registration was done by registrars
of the Netherlands Cancer Registry and personnel of the
individual hospitals. Patients receiving primary systemic
treatment without subsequent surgical treatment were not
registered in the NBCA. All female patients with primary
invasive breast cancer without distant metastases diag-
nosed between January 1, 2011 and December 31, 2015
were extracted from the NBCA.
Categories/Definitions
The surgical procedure was categorized as BCS or
mastectomy as determined by the final operative procedure
for the primary tumor. Patients who underwent BCS with
subsequent mastectomy as a second or third operative
procedure were categorized as having had a mastectomy.
Patients who had undergone a mastectomy were subdivided
by receipt of IBR. Of patients who had undergone BCS,
those who had received NAC were identified and catego-
rized as such. The endpoint of interest was BCPP, which
was the final outcome of local treatment obtained by one of
the following treatment strategies: (1) primary BCS, (2)
BCS after NAC, and (3) mastectomy followed by IBR. The
remaining patients underwent a mastectomy either primary
or following NAC.
Analysis
Descriptive statistics were used to describe the baseline
characteristics of the study population. The proportions of
patients who had undergone primary BCS were addressed
for the study period of 5 years, and the effect of age on the
rate of primary BCS was evaluated, as well as the variation
in these proportions between individual hospitals. Simi-
larly, the proportions within the categories that constituted
the group of patients who had undergone BCPP were
assessed and evaluated over time and in relation to age.
Time trends of the rate of patients who had received pri-
mary BCS were compared with BCPP. All analyses were
performed using SPSS 20 (IBM-SPSS Inc., Chicago).
RESULTS
During the study period, 61,309 patients were diagnosed
and surgically treated for primary invasive breast cancer in
89 Dutch hospitals. Patient and tumor characteristics are
summarized in Table 1. The median age of the patients was
61 years, and 74% of the patients were younger than
70 years old. The majority of patients were diagnosed with
invasive ductal carcinoma (81%), and most tumors were
staged as T1–2 (88%) and N0 (82%).
The frequencies of the treatment strategies leading to
preservation of the breast contour are listed in Table 2. In
67% of all patients, the breast contour was preserved
(BCPP): 53% of all patients (n = 32,520) underwent BCS
as the primary and definitive surgical treatment, 5% had
BCS following NAC (n = 3328), and 8% (n = 5023) of all
patients underwent mastectomy combined with IBR.
Patients who had received NAC accounted for one-tenth of
all patients who had undergone BCS, while one-fifth of
patients undergoing a mastectomy received IBR. Che-
motherapy was administered to 41% of all patients: 5% of
patients received NAC and subsequently underwent BCS,
7% of the patients received NAC and subsequently had a
mastectomy, while 29% of patients received adjuvant
chemotherapy.
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Trends Over Time
During 2011–2015, use of BCS following NAC and
mastectomy with IBR both increased, from 3 to 8% and 6
to 11% of all patients, respectively. As a result, the overall
frequency of BCPP increased significantly, from 63% in
2011 to 71% in 2015 (P\ 0.001; Fig. 1; Table 2), and the
proportion of patients who underwent a mastectomy
without reconstruction decreased from 37 to 29%, i.e., a
relative reduction of 22%. The proportion of patients
undergoing mere BCS for invasive cancer in The Nether-
lands remained stable during the study period. A gradual
increase was observed in the overall use of NAC, from 8%
in 2011 to 16% in 2015.
Age-Specific Frequency of BCS and BCPP
Table 2 presents the frequencies of the treatment
strategies per age group. The overall frequency of BCPP
was similar (approximately 70%) for all age categories,
except for patients C 70 years old (52%). The means used
to preserve the breast contour varied per age group. The
proportion of patients who underwent primary BCS was
lowest under 30 years (17%) and highest (63%) in patients
aged 60–69 years. With increasing age, both BCS after
NAC and mastectomy with IBR rates decreased. Above the
age of 70 years, a substantially lower percentage of pri-
mary BCS was observed (51%), and only a very low
percentage of BCS after NAC (1%) and IBR (1%). Almost
half of the oldest patients underwent a primary mastec-
tomy. Figure 2 shows the cumulative age-specific
proportions of the three treatment strategies to preserve the
breast contour.
Variation Between Hospitals
The proportion of patients undergoing BCPP varied
extensively between individual hospitals, and this range of
BCPP (47–88%) was wider than the observed variation of
BCS (37–67%). All three treatment strategies constituting
BCPP showed a wide variation between hospitals
(Table 2). There was an inverse relationship between the
proportion of primary BCS and the other two strategies to
preserve the breast contour per hospital (Fig. 3). The rates
of BCS after NAC and mastectomy combined with IBR
varied largely between hospitals: some hospitals never
used BCS after NAC nor mastectomy with IBR, while
other institutions performed BCS after NAC in up to 21%
and IBR in up to 28% of patients. Hospital volume did not
influence the institutional BCPP rate (data not shown).
DISCUSSION
We present BCPP as an esthetic local outcome measure
in breast cancer patients. BCPP provides a comprehensive
parameter encompassing various treatment strategies to
maintain the breast contour in patients treated for breast
cancer. While in The Netherlands the rate of BCS remained
stable during the study period, the rate of BCPP increased,
TABLE 1 Patient and tumor characteristics of 61,309 patients with
invasive breast cancer in 2011–2015
n (61,309) %
Age (years)
Below 30 305 1
30–39 2291 4
40–49 9139 15
50–59 16,058 26
60–69 17,788 29
70 or above 15,708 26
Histological subtype
Ductal 49,677 81
Lobular 6936 11
Combination of ductal and lobular 1601 3
Other or unknown 3095 5
Grade
I 14,233 23
II 26,340 43
III 15,431 25
Unknown 5305 9
Clinical tumor stage
cTx 1946 3
cT0 72 0
cTis 1488 2
cT1 35,495 58
cT2 18,304 30
cT3 2943 5
cT4 1061 2
Clinical nodal stage
cNx 1582 3
cN0 50,142 82
cN1 8697 14
cN2 323 1
cN3 565 1
Receptor type
HR positive, HER2 negative 43,280 71
HR positive, HER2 positive 5006 8
HR negative, HER2 positive 2400 4
Triple negative 6498 11
Unknown 4125 7
HR hormone receptor; HER2 human epidermal growth factor receptor
2
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from 63% in 2011 to 71% in 2015. This increase is the
result of increased use of BCS after NAC and mastectomy
with IBR.
To the best of the authors’ knowledge, no other studies
have described BCPP as a composite measure to evaluate
local esthetic outcome. Many studies have reported trends
of the separate surgical, reconstructive, and medical
modalities in patients treated for primary breast can-
cer.4,7–11 Population-based BCS rates have remained
stable in recent years in Brazil7 and The Netherlands,4
while an increase was observed in some other European
countries.11 Over a similar time period, a decrease in the
proportion of patients undergoing BCS was seen in the
USA (from 66.6% in 1998 to 61.9% in 2011).8,12–15 Other
studies have reported significant institutional and regional
differences in BCS rates, ranging from 20 to 84%.11,16–20
Increased use of mastectomy combined with IBR over
time, differences in IBR rates between countries,4,7,8,21–24
as well as more frequent application of NAC have also
been reported.4,5,25–28 The observed rise in the rate of
BCPP in relation to the observed stable primary BCS rate
demonstrates that the composite endpoint has additional
value as a local esthetic outcome parameter. This is
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TABLE 2 Surgical treatment
strategies for patients diagnosed
with invasive breast cancer,
separated by year of diagnosis
and age group, and hospital
differences
BCS BCS Mastectomy BCPP Mastectomy
NAC– NAC? IBR? IBR–
Total 32,520 53% 3328 5% 5023 8% 67% 20,438 33%
Year of diagnosis
2011 5699 54% 367 3% 682 6% 63% 3905 37%
2012 7283 54% 501 4% 920 7% 64% 4801 36%
2013 7152 53% 748 6% 1102 8% 67% 4525 34%
2014 7308 53% 957 7% 1286 9% 69% 4377 31%
2015 5078 52% 755 8% 1033 11% 71% 2830 29%
Age group (years)
Below 30 52 17% 39 13% 133 44% 73% 81 27%
30–39 619 27% 311 14% 593 26% 67% 768 34%
40–49 3522 39% 1084 12% 1566 17% 68% 2967 33%
50–59 9107 57% 1147 7% 1715 11% 75% 4089 26%
60–69 11,281 63% 662 4% 839 5% 72% 5006 28%
70 or above 7931 51% 83 1% 175 1% 52% 7519 48%
Hospitals
Mean. n.a. 53% n.a. 5% n.a. 8% 67% n.a. 33%
Min. n.a. 34% n.a. 0% n.a. 0% 47% n.a. 12%
Max. n.a. 67% n.a. 21% n.a. 28% 88% n.a. 53%
NAC Neoadjuvant chemotherapy, IBR immediate breast reconstruction, BCS breast-conserving surgery,
BCPP breast-contour-preserving procedure, n.a. not applicable
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illustrated in the present study, since a stable rate of pri-
mary BCS masks a 22% proportional decrease of patients
who underwent a plain mastectomy.
The BCPP rate was similar for most age groups, but the
strategies used to maintain the breast contour varied largely
between the different age groups. Primary BCS was
increasingly used when patients were older, and a
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concomitant decrease was observed for the proportions of
patients who underwent BCS after NAC and those who
underwent mastectomy with IBR. In the very young age
group, IBR accounted for half of the patients in whom the
breast contour was preserved. The difference in the pro-
portion of patients who had primary BCS in relation to the
overall proportion undergoing BCPP (17% and 73%,
respectively) was most profound in these very young
patients (\ 30 years old). This is in part explained by
previous guidelines advising against BCS in the young
because of the higher risk of local recurrence and diag-
nosed genetic mutations.29
In patients aged [ 70 years, the low rate of BCPP
merely reflected the rate of BCS, since BCS after NAC and
mastectomy with IBR were infrequently used (1% and 1%,
respectively). The absence of evidence in support of
adjuvant chemotherapy in patients older than 70 years
explains why NAC was hardly ever administered. The low
rate of mastectomy with IBR seems conceivable too,
although the extent to which patient preferences explain the
observed higher mastectomy rate remains unanswered.
BCPP as such was of little additional value in these elderly
patients.
The rate of BCS has been promulgated as a quality
indicator.30 When performing primary BCS, a delicate
balance exists between the esthetic and oncological aims of
the surgery: a wider excision may lead to a worse esthetic
result, while too narrow an excision may leave residual
tumor tissue. Striving for a high BCS rate may uninten-
tionally lead to the perverse incentive of aiming for the
lowest possible positive margin rates by resecting larger
amounts of breast tissue. BCPP serves the aim of mea-
suring esthetic outcome more appropriately, as it
appreciates at least the combined efforts and different
treatment strategies to maintain the shape of the breast,
which is in itself a desirable esthetic outcome.
While BCPP more or less annihilated conventional age-
specific BCS rates, no such effect was observed for insti-
tutional differences. Despite an apparent interplay between
the various strategies used to preserve the breast contour
(illustrated by the observed inverse association between the
rate of BCS and the proportion of patients who underwent
BCPP), the net effect of the hospital variation in BCS after
NAC and mastectomy with IBR resulted in an observed
wider range of the proportion of BCPP than the hospital
variation in BCS rates. Previous studies using data from the
NBCA studied the variation of NAC rates25 and the pro-
portion of patients undergoing mastectomy combined with
IBR.21,31 Patient and tumor characteristics and hospital
factors did account for institutional variation, but the
number of treated patients per hospital was not a factor
associated with higher rates of NAC or IBR. In another
study, we also observed that surgeons’ and plastic
surgeons’ preferences had an impact on the institutional
IBR rate.32 Much of the observed institutional variation
remains unexplained. Several hospitals in the present study
that never applied NAC or provided IBR might explain the
wider range of BCPP rates. As these hospitals had no
means other than primary BCS to enhance their BCPP rate,
these institutions fell behind as others were improving their
BCPP rate. Obviously, this hypothesis urges the need for
additional in-depth analysis of the observed institutional
variation.
Having a national multidisciplinary audit for breast
cancer care enabled us to analyze questions with large
numbers of patients. This is a strength of the present study,
and the population-based data are also suitable to study
time trends. The absence of information regarding impor-
tant patient characteristics such as smoking status and body
mass index is a limitation of the NBCA. These factors may
well affect the eligibility of patients to undergo immediate
breast reconstruction. Moreover, the lack of data about
delayed reconstruction may limit the interpretation of
results since to some extent. In addition, institutional
availability and use of oncoplastic surgical techniques as
well as radiotherapy indications have an impact on the
desirability to perform BCS or prosthesis use, respectively.
However, data regarding the use of oncoplastic techniques
lacked sufficient detail to take into consideration. Referral
patterns between hospitals, e.g., patients who underwent
surgery at an institution another than the hospital where
NAC was administered, could not be addressed. Finally,
information regarding the achieved and perceived success
of BCS as well as of an immediate breast reconstruction
was not available, but would importantly enhance the value
of BCPP as an outcome parameter.
BCPP provides insight into the various ways in which
breast cancer patients can retain their breast contour, and
the result reflects combined multidisciplinary efforts.
Although it still lacks information about the perceived
esthetic outcome, BCPP is an important step in providing
more information than the rate of BCS alone. Achievement
of a 100% preservation score is not considered to be an
ultimate goal. We acknowledge that multiple factors
influence the treatment options that can and will be offered
to patients, and the patient’s decision. Notwithstanding
these limitations, this study supports the use of the BCPP
rate as a local outcome parameter, and an institutional
BCPP rate of 75% in patients younger than 70 years may
well be defined as an appropriate norm value for good
esthetic outcome of local treatment.
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CONCLUSIONS
BCPP as a composite parameter provides insight into
and understanding of the preservation of the breast contour
in primary breast cancer patients, appreciating the various
ways to maintain the contour of the breast. This study
demonstrates that, while the BCS rate remained stable over
recent years, the proportion of patients in whom the breast
contour was preserved increased while the proportion who
underwent a plain mastectomy decreased by one-fifth. At
the same time, unexplained institutional differences in the
BCS rate persist when applying the rate of BCPP as a
quality indicator, and this should motivate future research.
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